A5100440076- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Cancer Genomics and Diagnostics
- Colorectal Cancer Treatments and Studies
- Lung Cancer Diagnosis and Treatment
- HER2/EGFR in Cancer Research
- Neuroendocrine Tumor Research Advances
- Cancer therapeutics and mechanisms
- Pancreatic and Hepatic Oncology Research
- Cancer Cells and Metastasis
- Cancer, Hypoxia, and Metabolism
- Metabolomics and Mass Spectrometry Studies
- RNA modifications and cancer
- Sarcoma Diagnosis and Treatment
- Gastric Cancer Management and Outcomes
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer, Lipids, and Metabolism
- Metastasis and carcinoma case studies
- Cancer Research and Treatments
- Radiomics and Machine Learning in Medical Imaging
- Fibroblast Growth Factor Research
- Peptidase Inhibition and Analysis
- Genetic factors in colorectal cancer
- Photodynamic Therapy Research Studies
- PI3K/AKT/mTOR signaling in cancer
Xiamen University
2025
Shenzhen University
2025
Soochow University
2024
Chinese Academy of Medical Sciences & Peking Union Medical College
2015-2024
First Affiliated Hospital of Soochow University
2024
East China University of Science and Technology
2022-2024
Wuhan University
2017-2023
Renmin Hospital of Wuhan University
2017-2023
Peking Union Medical College Hospital
2022
National Cancer Center
2019
Significance In a few milliliters of blood from cancer patient, one can isolate circulating tumor cells (CTCs). Originating the primary tumor, CTCs seed metastases, which account for majority cancer-related deaths. We demonstrate analyses whole genome single CTCs, are highly needed personalized treatment. discovered that copy number variations (CNVs), major genomic variations, specific to types, reproducible cell cell, and even patient patient. hypothesize CNVs at certain loci selected lead...
Purpose Mutations in the epidermal growth factor receptor (EGFR) kinase domain can predict tumor response to tyrosine inhibitors (TKIs) non–small-cell lung cancer (NSCLC). However, obtaining tissues for mutation analysis is challenging. We hypothesized that plasma-based EGFR feasible and has value predicting patients with NSCLC. Patients Methods Plasma DNA samples matched tumors from 230 stages IIIB IV NSCLC were analyzed mutations exons 19 21 by using denaturing high-performance liquid...
EGFR mutation is a predictor of epidermal growth factor receptor-tyrosine kinase inhibitor treatment response in patients with non-small-cell lung cancer (NSCLC). However, it remains unclear whether chemotherapy affects status NSCLC. We investigated the influence on mutations plasma and tumor tissues from NSCLC.Samples were derived three cohorts: one, 264 advanced NSCLC who received first-line matched pre- postchemotherapy blood samples; two, 63 stages IIb to IIIb disease post-neoadjuvant...
Osteosarcoma is the most common primary bone malignancy, and lung frequent site of metastasis. The limited understanding tumoral heterogeneity evolutionary process genomic alterations in pulmonary metastatic osteosarcoma impedes development novel therapeutic strategies. Here we systematically illustrate disparities between tumors corresponding by multiregional whole-exome whole-genome sequencing 86 tumor regions from 10 patients with osteosarcoma. Metastatic exhibited a significantly higher...
Background Among advanced non-small cell lung cancer (NSCLC) patients with an acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI), about 50% carry the T790M mutation, but this frequency in EGFR-TKI-naïve and dynamic change during therapy remains unclear. This study investigated quantification of mutation plasma cell-free DNA (cf-DNA) NSCLC assess clinical outcomes EGFR-TKI therapy. Materials Methods We retrospectively 135 who obtained...
Pancreatic cancer is highly malignant and characterised by rapid uncontrolled growth. While some of the important regulatory networks involved in pancreatic have been determined, relevant genes not fully identified.We screened that may control proliferation seven pairs matched normal tissue samples. We examined KIF15 expression tissues effect on cell vitro vivo. The mechanisms underlying promotion were investigated.mRNA microarray functional analysis identified 22 potentially play an role...
Non-small cell lung cancer (NSCLC) with KRAS mutation may be resistant to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI). This study aims evaluate a plasma-based analysis and the clinical significance of plasma as predictive marker for tumor resistance EGFR-TKIs in patients NSCLC.DNA extracted from matched tissues were obtained 273 advanced stage NSCLC. Patients followed up prospectively treatment outcomes. mutations codon 12 13 detected using PCR-restriction fragment...
Purpose This study evaluated occurrence and potential clinical significance of intratumoral EGFR mutational heterogeneity in Chinese patients with non-small cell lung cancer (NSCLC). Materials Methods Eighty-five stage IIIa-IV NSCLC who had undergone palliative surgical resection were included this study. Of these, 45 carried mutations (group-M) 40 wild-type (group-W). Each tumor sample was microdissected to yield 28–34 foci Intratumoral mutation determined using Denaturing High Performance...
// Xue Yang 1, * , Minglei Zhuo Xin Ye 2 Hua Bai 1 Zhijie Wang Yun Sun Jun Zhao Tongtong An Jianchun Duan Meina Wu Jie Department of Thoracic Medical Oncology, Key Laboratory Carcinogenesis and Translational Research (Ministry Education), Peking University Cancer Hospital Institute, Beijing, China Asia Emerging Markets Innovative Medicine AstraZeneca R & D, Shanghai, These authors contributed equally to this work Correspondence to: Wang, e-mail: zlhuxi@163.com Keywords: non-small-cell lung...
Abstract Purpose: Genomic analyses of small-cell lung cancer (SCLC) are limited by the availability tumor specimens. This study aimed to investigate suitability single-cell sequencing circulating cells (CTC) as a method inferring evolution and progression SCLCs. Experimental Design: Between July 1, 2011, 28, 2014, 48 consecutively diagnosed patients with SCLC were recruited for this study. CTCs captured from each patient CellSearch system. Somatic mutations copy number alterations (CNA)...
Purpose: No validated biomarkers that could identify the subset of patients with lung adenocarcinoma who might benefit from chemotherapy have yet been well established. This study aimed to explore potential biomarker model predictive efficacy and survival outcomes after first-line pemetrexed plus platinum doublet based on metabolomics profiling.Experimental Design: In total, 354 consecutive eligible were assigned receive in combination either cisplatin or carboplatin. Prospectively collected...
Abstract Even though the general mechanism of photodynamic cancer therapy is known, details and consequences reactions between photosensitizer‐generated singlet oxygen substrate molecules remain elusive at molecular level. Using temoporfin as photosensitizer, here we combine field‐induced droplet ionization mass spectrometry acoustic levitation techniques to study “wall‐less” oxidation 18:1 cardiolipin 1‐palmitoyl‐2‐oleoyl‐sn‐glycero‐3‐phospho‐(1′‐rac‐glycerol) (POPG) mediated by air–water...
8093 Background: SCLC is characterized by a high rate of proliferation and poor prognosis, new therapies are urgently needed. B7-H3 highly expressed in SCLC. HS-20093, B7-H3-targeted antibody-drug conjugate (ADC), demonstrated antitumor activity advanced solid tumors the dose escalation part ARTEMIS-001 study (Jie Wang et al., JCO, 2023) (NCT05276609). Here, we present results on efficacy safety expansion doses patients (pts) with from phase 1a/b. Methods: consisted (1a) (1b) part. Pts were...
Epidermal growth factor receptor (EGFR) mutations, including a known exon 19 deletion (19 del) and 21 L858R point mutation (L858R mutation), are strong predictors of the response to EGFR tyrosine kinase inhibitor (EGFR-TKI) treatment in lung adenocarcinoma. However, whether patients carrying del mutations exhibit different responsiveness EGFR-TKIs what potential mechanism for this difference remain controversial. This study aimed investigate clinical outcomes EGFR-TKI with explore genetic...
Glycolysis is the most predominant metabolic reprogramming of pancreatic cancer (PC), underlying mechanism which in PC cells remains unclear. In this study, we found for first time that KIF15 promotes glycolytic capacity and tumor growth. Moreover, expression was negatively correlated with prognosis patients. The ECAR OCR measurements indicated knockdown significantly impaired cells. Western blotting demonstrated glycolysis molecular markers decreased rapidly after KIF15. Further experiments...
Abstract Background It is well known that genetic alternation of epidermal growth factor receptor ( EGFR ) plays critical roles in tumorgenesis lung cancer and can predict outcome non-small-cell treatment, especially the tyrosine-kinase inhibitors (EGFR-TKIs) therapy. However, it unclear whether epigenetic changes such as DNA methylation involve response to EGFR-TKI Methods Tumor samples from 155 patients with stages IIIB IV NSCLC who received therapy were analyzed for status Wnt antagonist...
<b><i>Objective:</i></b> To identify the clinicopathological characteristics and clinical outcomes of Chinese patients with non-small cell lung cancer (NSCLC) to investigate possible associations NSCLC echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) epidermal growth factor receptor (EGFR) mutations. <b><i>Methods:</i></b> Patients stage IV were screened for EML4-ALK rearrangement EGFR mutations at Peking...
The validity of epidermal growth factor receptor (EGFR) mutation in serum and plasma DNA as a surrogate tumor tissue has been comprehensively explored. However, the concordance between peripheral blood samples EGFR detection remains variable. question to whether real-time for analysis are required before tyrosine kinase inhibitor (EGFR-TKI) therapy unanswered. This study included two cohorts:(i) 822 non-small cell lung cancer (NSCLC) patients with primary matched at initial diagnosis; (ii)...
EGFR mutation is a strong predictive factor of EGFR-TKIs therapy. However, at least 10% patients with wild-type are responsive to TKIs, suggesting that other determinants outcome besides might exist. We hypothesized activation phosphorylated could be potential biomarker treatment among in EGFR. Total 205 stage IIIb and IV NSCLC patients, tissue samples whom were available for molecular analysis, enrolled this study. The phosphorylation tyrosine 1068 (pTyr1068) 1173 (pTyr1173) assessed by...